search
Back to results

Respiratory Impact of LA Volume After IS Block

Primary Purpose

Arthroscopic Surgery of the Shoulder, Extrafascial Interscalene Plexus Brachial Block

Status
Recruiting
Phase
Phase 4
Locations
Switzerland
Study Type
Interventional
Intervention
Ropivacaine 0.75% Injectable Solution
Ropivacaine 0.75% Injectable Solution
Sponsored by
Eric Albrecht
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Arthroscopic Surgery of the Shoulder

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • arthroscopic surgery of the shoulder
  • ASA class 1 to 3
  • age more than 18 years old

Exclusion Criteria:

  • patient refusal or inability to understand and/or sign the inform consent
  • contraindication for perineural block (allergy to local anesthetics, infection of puncture site, major coagulopathy, sensitive or motor deficiency on the operative side arm
  • chronic alcool abuse
  • opioid drug abuse or under substitution treatment
  • patients known for allergies to paracetamol, non steroidal anti inflammatory drugs, dexamethasone, sulfate magnesium, ondansetron, droperidol, and omeprazole;
  • patients under chronic corticotherapy
  • patients known for malignant hyperthermia;
  • patients with chronic kidney failure (Glomerular Filtration Rate < 20 ml/min)
  • patients with severe pulmonary disease
  • patients with history of neck surgery or radiotherapy on the operative side;
  • pregnancy

Sites / Locations

  • CHUV (Centre Hospitalier Universitaire Vaudois)Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

10 ml single-shot injection

20 ml single-shot injection group

Arm Description

In the 10ml group, participants will have an interscalene brachial plexus with an extrafascial injection of 10 ml ropivacaine 0.75% at the level of C5-C6 nerves roots. Participants will also receive multimodal analgesia with injection of dexamethasone 8 mg iv, magnesium sulfate 40 mg kg^-1 iv, ketorolac 30 mg iv, and acetaminophen 1000 mg iv, according to the current practice in our institution.

In the 20ml group, participants will have an interscalene brachial plexus with an extrafascial injection of 20 ml ropivacaine 0.75% at the level of C5-C6 nerves roots. Participants will also receive multimodal analgesia with injection of dexamethasone 8 mg iv, magnesium sulfate 40 mg kg^-1 iv, ketorolac 30 mg iv, and acetaminophen 1000 mg iv, according to the current practice in our institution.

Outcomes

Primary Outcome Measures

Incidence of hemidiaphragmatic paralysis

Secondary Outcome Measures

Incidence of hemidiaphragmatic paralysis
Presence of Dyspnea
Verbal question to the patient if he has dyspnea or not
Presence of PONV
Verbal question to the patient if he has dyspnea or not
Presence of Pruritus
Verbal question to the patient if he has pruritus or not
Presence of Claude-Bernard-Horner syndrome
Examination of the patient
Presence of Dysphonia
Verbal question to the patient if he has dysphonia or not
Forced expiratory volume in one second
in liters per second
Forced vital capacity
in liters
Peak expiratory flow
in liters per second
Installation time of sensory block
in minutes
Installation time of motor block
in minutes
Time to first dose of postoperative iv morphine
in hours
Pain scores at rest
Numeric pain intensity scale. Pain scores range from zero (no pain) to 10 (worst possible pain)
Pain scores on movement
Numeric pain intensity scale. Pain scores range from zero (no pain) to 10 (worst possible pain).
Cumulative postoperative iv morphine consumption
in milligrams
Duration of analgesic block
in minutes
Duration of motor block
in minutes
Duration of sensory block
in minutes
Satisfaction of the participants
Numeric satisfaction intensity scale. Satisfactions range from 0 (totally unsatisfied) to 10 (maximal satisfaction).

Full Information

First Posted
January 22, 2021
Last Updated
October 7, 2022
Sponsor
Eric Albrecht
search

1. Study Identification

Unique Protocol Identification Number
NCT04726280
Brief Title
Respiratory Impact of LA Volume After IS Block
Official Title
Respiratory Impact of Local Anaesthetic Volume for an Interscalene Brachial Plexus Block With an Extrafascial Approach.
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
February 1, 2021 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Eric Albrecht

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The hypothesis of this study is that a reduced extrafascial volume of local anesthetic for an interscalene brachial plexus block is associated with a lower incidence of diaphragmatic hemiparalysis after an arthroscopic surgery of the shoulder, without any reduction of the analgesic efficacy.
Detailed Description
The hypothesis of this study is that a reduced extrafascial volume of local anesthetic for an interscalene brachial plexus block is associated with a lower incidence of diaphragmatic hemiparalysis after an arthroscopic surgery of the shoulder, without any reduction of the analgesic efficacy. Our prospective randomized controlled trial will include two parallel groups: a group will receive a volume of 20 mls of ropivacaine 0.75%, while the other group will receive a volume of 10 mls. All participants will have a preoperative ultrasound-guided interscalene brachial plexus with an extrafascial injection of 10 or 20 mls of ropivacaine 0.75%. In both groups, participants will have an examination of the hemidiaphgragm with the ultrasound, before and 30 min after the block. The respiratory function will also be assessed with a bedside spirometer before and after the block, and at 12 and 24 postoperative hours. During surgery all participants will receive multimodal analgesia inclusive of iv dexamethasone 8 mg, iv magnesium sulfate 40 milligram kg^2, iv ketorolac 30 milligrams, and iv acetaminophen 1000 milligrams, according to the current practice in our institution. In the postoperative period, Participants will be prescribed an IV pca of morphine. Assignment to one of these two groups will be done according to a computer-generated list of random numbers, and the sealed envelopes method will be used.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Arthroscopic Surgery of the Shoulder, Extrafascial Interscalene Plexus Brachial Block

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
10 ml single-shot injection
Arm Type
Experimental
Arm Description
In the 10ml group, participants will have an interscalene brachial plexus with an extrafascial injection of 10 ml ropivacaine 0.75% at the level of C5-C6 nerves roots. Participants will also receive multimodal analgesia with injection of dexamethasone 8 mg iv, magnesium sulfate 40 mg kg^-1 iv, ketorolac 30 mg iv, and acetaminophen 1000 mg iv, according to the current practice in our institution.
Arm Title
20 ml single-shot injection group
Arm Type
Active Comparator
Arm Description
In the 20ml group, participants will have an interscalene brachial plexus with an extrafascial injection of 20 ml ropivacaine 0.75% at the level of C5-C6 nerves roots. Participants will also receive multimodal analgesia with injection of dexamethasone 8 mg iv, magnesium sulfate 40 mg kg^-1 iv, ketorolac 30 mg iv, and acetaminophen 1000 mg iv, according to the current practice in our institution.
Intervention Type
Drug
Intervention Name(s)
Ropivacaine 0.75% Injectable Solution
Intervention Description
10 ml extrafascial interscalene brachial plexus block
Intervention Type
Drug
Intervention Name(s)
Ropivacaine 0.75% Injectable Solution
Intervention Description
20 ml extrafascial interscalene brachial plexus block
Primary Outcome Measure Information:
Title
Incidence of hemidiaphragmatic paralysis
Time Frame
30 minutes after the interscalene plexus brachial extrafascial injection
Secondary Outcome Measure Information:
Title
Incidence of hemidiaphragmatic paralysis
Time Frame
at 2 and 24 postoperative hours
Title
Presence of Dyspnea
Description
Verbal question to the patient if he has dyspnea or not
Time Frame
in phase 1 recovery and at 12 and 24 postoperative
Title
Presence of PONV
Description
Verbal question to the patient if he has dyspnea or not
Time Frame
in phase 1 recovery and at 12 and 24 postoperative
Title
Presence of Pruritus
Description
Verbal question to the patient if he has pruritus or not
Time Frame
in phase 1 recovery and at 12 and 24 postoperative hours
Title
Presence of Claude-Bernard-Horner syndrome
Description
Examination of the patient
Time Frame
in phase 1 recovery and at 12 and 24 postoperative hours
Title
Presence of Dysphonia
Description
Verbal question to the patient if he has dysphonia or not
Time Frame
in phase 1 recovery and at 12 and 24 postoperative hours
Title
Forced expiratory volume in one second
Description
in liters per second
Time Frame
30 minutes after the interscalene plexus brachial extrafascial injection, and at 2, 12 and 24 postoperative hours
Title
Forced vital capacity
Description
in liters
Time Frame
30 minutes after the interscalene plexus brachial extrafascial injection, and at 2, 12 and 24 postoperative hours
Title
Peak expiratory flow
Description
in liters per second
Time Frame
30 minutes after the interscalene plexus brachial extrafascial injection, and at 2, 12 and 24 postoperative hours
Title
Installation time of sensory block
Description
in minutes
Time Frame
up to 30 minutes after the interscalene plexus brachial extrafascial injection
Title
Installation time of motor block
Description
in minutes
Time Frame
up to 30 minutes after the interscalene plexus brachial extrafascial injection
Title
Time to first dose of postoperative iv morphine
Description
in hours
Time Frame
up to 24 hours postsurgery
Title
Pain scores at rest
Description
Numeric pain intensity scale. Pain scores range from zero (no pain) to 10 (worst possible pain)
Time Frame
in phase 1 recovery and at 12 and 24 postoperative hours
Title
Pain scores on movement
Description
Numeric pain intensity scale. Pain scores range from zero (no pain) to 10 (worst possible pain).
Time Frame
in phase 1 recovery and at 12 and 24 postoperative hours
Title
Cumulative postoperative iv morphine consumption
Description
in milligrams
Time Frame
in phase 1 recovery and at 12 and 24 postoperative hours
Title
Duration of analgesic block
Description
in minutes
Time Frame
up to 24 hours postsurgery
Title
Duration of motor block
Description
in minutes
Time Frame
up to 24 hours postsurgery
Title
Duration of sensory block
Description
in minutes
Time Frame
up to 24 hours postsurgery
Title
Satisfaction of the participants
Description
Numeric satisfaction intensity scale. Satisfactions range from 0 (totally unsatisfied) to 10 (maximal satisfaction).
Time Frame
at 24 postoperative hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: arthroscopic surgery of the shoulder ASA class 1 to 3 age more than 18 years old Exclusion Criteria: patient refusal or inability to understand and/or sign the inform consent contraindication for perineural block (allergy to local anesthetics, infection of puncture site, major coagulopathy, sensitive or motor deficiency on the operative side arm chronic alcool abuse opioid drug abuse or under substitution treatment patients known for allergies to paracetamol, non steroidal anti inflammatory drugs, dexamethasone, sulfate magnesium, ondansetron, droperidol, and omeprazole; patients under chronic corticotherapy patients known for malignant hyperthermia; patients with chronic kidney failure (Glomerular Filtration Rate < 20 ml/min) patients with severe pulmonary disease patients with history of neck surgery or radiotherapy on the operative side; pregnancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Eric Albrecht
Phone
0041795566341
Email
eric.albrecht@chuv.ch
First Name & Middle Initial & Last Name or Official Title & Degree
Erin Gonvers
Phone
0041795560194
Email
erin.gonvers@chuv.ch
Facility Information:
Facility Name
CHUV (Centre Hospitalier Universitaire Vaudois)
City
Lausanne
State/Province
Vaud
ZIP/Postal Code
1011
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eric Albrecht, MD
Phone
+41 79 556 63 41
Email
eric.albrecht@chuv.ch
First Name & Middle Initial & Last Name & Degree
Erin Gonvers
Phone
+41 79 556 01 94
Email
erin.gonvers@chuv.ch
First Name & Middle Initial & Last Name & Degree
Eric Albrecht, MD

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Respiratory Impact of LA Volume After IS Block

We'll reach out to this number within 24 hrs